Cargando…

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method

The SARS-CoV-2 outbreak caused an unprecedented global public health threat, having a high transmission rate with currently no drugs or vaccines approved. An alternative powerful additional approach to counteract COVID-19 is in silico drug repurposing. The SARS-CoV-2 main protease is essential for v...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sencanski, Milan, Perovic, Vladimir, Pajovic, Snezana B., Adzic, Miroslav, Paessler, Slobodan, Glisic, Sanja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503980/ https://www.ncbi.nlm.nih.gov/pubmed/32842509 http://dx.doi.org/10.3390/molecules25173830

Ejemplares similares

In silico analysis suggests repurposing of ibuprofen for prevention and treatment of EBOLA virus disease
por: Veljkovic, Veljko, et al.
Publicado: (2015)

Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors
por: Radosevic, Draginja, et al.
Publicado: (2019)

Identification of SARS‐CoV‐2 Papain‐like Protease (PLpro) Inhibitors Using Combined Computational Approach
por: Sencanski, Milan, et al.
Publicado: (2022)

In Silico and In Vitro Inhibition of SARS-CoV-2 PL(pro) with Gramicidin D
por: Protić, Sara, et al.
Publicado: (2023)

In Silico Screening of Natural Compounds for Candidates 5HT6 Receptor Antagonists against Alzheimer’s Disease
por: Bojić, Tijana, et al.
Publicado: (2022)

Arginase Flavonoid Anti-Leishmanial in Silico Inhibitors Flagged against Anti-Targets
por: Glisic, Sanja, et al.
Publicado: (2016)

Identification of Candidate Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor Which May Improve Vagus Nerve Stimulation in Chronic Tinnitus
por: Bojić, Tijana, et al.
Publicado: (2017)

Novel Entropy-Based Phylogenetic Algorithm: A New Approach for Classifying SARS-CoV-2 Variants
por: Perovic, Vladimir, et al.
Publicado: (2023)

Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection
por: Veljkovic, Veljko, et al.
Publicado: (2015)

In silico analysis suggests interaction between Ebola virus and the extracellular matrix
por: Veljkovic, Veljko, et al.
Publicado: (2015)

Simple Chemoinformatics Criterion Using Electron Donor-Acceptor Molecular Characteristics for Selection of Antibiotics Against Multi-Drug-Resistant Bacteria
por: Veljkovic, Veljko, et al.
Publicado: (2016)

Common molecular mechanism of the hepatic lesion and the cardiac parasympathetic regulation in chronic hepatitis C infection: a critical role for the muscarinic receptor type 3
por: Glišić, Sanja, et al.
Publicado: (2016)

A simple method for calculation of basic molecular properties of nutrients and their use as a criterion for a healthy diet
por: Veljkovic, Veljko, et al.
Publicado: (2017)

Evolution of 2014/15 H3N2 Influenza Viruses Circulating in US: Consequences for Vaccine Effectiveness and Possible New Pandemic
por: Veljkovic, Veljko, et al.
Publicado: (2015)

Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China
por: Veljkovic, Veljko, et al.
Publicado: (2016)

In silico Therapeutics for Neurogenic Hypertension and Vasovagal Syncope
por: Bojić, Tijana, et al.
Publicado: (2016)

Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study
por: Refaey, Rana H., et al.
Publicado: (2021)

Possible repurposing of seasonal influenza vaccine for prevention of Zika virus infection
por: Veljkovic, Veljko, et al.
Publicado: (2016)

In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing
por: Kumar, Yogesh, et al.
Publicado: (2020)

Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023)

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease
por: Yang, Kai S., et al.
Publicado: (2022)

SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones
por: BATIBAY, Gönül S., et al.
Publicado: (2023)

Evolution of SARS-CoV-2 virus and assessment of the effectiveness of COVID-19 vaccine
por: Veljkovic, Veljko, et al.
Publicado: (2021)

Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an in silico repurposing study
por: Ferraz, Witor Ribeiro, et al.
Publicado: (2020)

In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021)

Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents
por: Ahmed, Mohammad Z., et al.
Publicado: (2021)

In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors
por: Ibrahim, Mahmoud A. A., et al.
Publicado: (2021)

In silico assessment of diterpenes as potential inhibitors of SARS-COV-2 main protease
por: Abdelrady, Yousef A, et al.
Publicado: (2023)

Repurposing metocurine as main protease inhibitor to develop novel antiviral therapy for COVID-19
por: Jain, Rashi, et al.
Publicado: (2020)

In Silico Discovery of a Substituted 6-Methoxy-quinalidine with Leishmanicidal Activity in Leishmania infantum
por: Stevanović, Strahinja, et al.
Publicado: (2018)

Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M(pro)) of SARS-CoV-2
por: Silva, José Rogério A., et al.
Publicado: (2021)

A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors
por: Jo, Seri, et al.
Publicado: (2022)

From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease †
por: Göhl, Matthias, et al.
Publicado: (2022)

An in-silico investigation of potential natural polyphenols for the targeting of COVID main protease inhibitor
por: Aljarba, Nada H., et al.
Publicado: (2022)

In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus
por: Eleftheriou, Phaedra, et al.
Publicado: (2020)

2-Phenoxyacetamide derivatives as SARS-CoV-2 main protease inhibitor: In silico studies
por: Hariyono, Pandu, et al.
Publicado: (2022)

Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach
por: Farhat, Ameny, et al.
Publicado: (2022)

In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor
por: Wen, Lei, et al.
Publicado: (2021)

In Silico Discovery of Small-Molecule Inhibitors Targeting SARS-CoV-2 Main Protease
por: Gao, Menghan, et al.
Publicado: (2023)

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease
por: Baker, Jeremy D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bt6v2svbsrv9n9oa4g9fu393v3